43% of Medicaid managed care plans require prior authorization for buprenorphine, causing 82% treatment abandonment risk during the approval window

43% of Medicaid managed care plans require prior authorization before covering buprenorphine prescriptions, creating a bureaucratic delay during the narrow window when patients with opioid use disorder are motivated to begin treatment. Medicaid is the largest single payer for addiction medications, and 19.1 million individuals were disenrolled from Medicaid by March 2024 after the COVID-era continuous coverage requirement ended. Why it matters: a patient presenting at a clinic or emergency department ready to start buprenorphine faces days-long prior authorization delays, so the motivation window closes and 82% of physicians report that prior authorization leads patients to abandon treatment entirely, so patients return to illicit opioid use during the waiting period, so the healthcare system's own insurance bureaucracy becomes a direct contributor to overdose deaths, so the massive public investment in expanding MOUD access (X-waiver elimination, telehealth expansion) is undermined at the pharmacy counter by payer-level gatekeeping. The structural root cause is that Medicaid managed care organizations use prior authorization as a cost-containment tool without carving out exceptions for time-sensitive addiction medications, and because federal regulations only require standard prior authorization decisions within 14 calendar days (being shortened to 7 days in January 2026), the approval timeline is fundamentally mismatched with the clinical urgency of opioid use disorder treatment initiation.